333 related articles for article (PubMed ID: 30591192)
1. Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India.
Singh V; Guleria P; Malik PS; Mohan A; Thulkar S; Pandey RM; Luthra K; Arava S; Ray R; Jain D
Curr Probl Cancer; 2019 Oct; 43(5):391-401. PubMed ID: 30591192
[TBL] [Abstract][Full Text] [Related]
2. PCR-based detection of EGFR, ALK, KRAS and BRAF mutations in Russian patients with lung adenocarcinoma: a single-center experience.
Mitiushkina NV; Kholmatov MM; Venina AR; Tiurin VI; Yanus GA; Sokolova TN; Yatsuk OS; Zaitseva OA; Ivantsov AO; Kuligina ES; Togo AV; Imyanitov EN
Neoplasma; 2018 Nov; 65(6):972-979. PubMed ID: 30334450
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
[TBL] [Abstract][Full Text] [Related]
4. Detection of EGFR, KRAS and BRAF mutations in metastatic cells from cerebrospinal fluid.
Frankel D; Nanni-Metellus I; Robaglia-Schlupp A; Tomasini P; Guinde J; Barlesi F; Astoul P; Ouafik L; Amatore F; Secq V; Kaspi E; Roll P
Clin Chem Lab Med; 2018 Apr; 56(5):851-856. PubMed ID: 29306909
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
Kinno T; Tsuta K; Shiraishi K; Mizukami T; Suzuki M; Yoshida A; Suzuki K; Asamura H; Furuta K; Kohno T; Kushima R
Ann Oncol; 2014 Jan; 25(1):138-42. PubMed ID: 24297085
[TBL] [Abstract][Full Text] [Related]
6. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ
Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673
[TBL] [Abstract][Full Text] [Related]
7. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
[TBL] [Abstract][Full Text] [Related]
8. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
9. EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies.
Forest F; Stachowicz ML; Casteillo F; Karpathiou G; Gouzy-Grosjean F; Guilaubey C; Cottier M; Beal J; Clemenson A; Péoc'h M
Exp Mol Pathol; 2017 Dec; 103(3):306-310. PubMed ID: 29175303
[TBL] [Abstract][Full Text] [Related]
10. EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma.
Colombino M; Paliogiannis P; Cossu A; Santeufemia DA; ; Sini MC; Casula M; Palomba G; Manca A; Pisano M; Doneddu V; Palmieri G
BMC Pulm Med; 2019 Nov; 19(1):209. PubMed ID: 31711449
[TBL] [Abstract][Full Text] [Related]
11. Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study.
Paliogiannis P; Colombino M; Sini MC; Manca A; Casula M; Palomba G; Pisano M; Doneddu V; Zinellu A; Santeufemia D; ; Sotgiu G; Cossu A; Palmieri G
BMC Pulm Med; 2022 Jan; 22(1):32. PubMed ID: 35012520
[TBL] [Abstract][Full Text] [Related]
12. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.
Johnson ML; Sima CS; Chaft J; Paik PK; Pao W; Kris MG; Ladanyi M; Riely GJ
Cancer; 2013 Jan; 119(2):356-62. PubMed ID: 22810899
[TBL] [Abstract][Full Text] [Related]
13. Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients.
Bhaumik S; Ahmad F; Das BR
Med Oncol; 2016 Oct; 33(10):117. PubMed ID: 27637917
[TBL] [Abstract][Full Text] [Related]
14. Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations.
Li M; Zhang L; Tang W; Duan JC; Jin YJ; Qi LL; Wu N
Cancer Imaging; 2019 Nov; 19(1):77. PubMed ID: 31783917
[TBL] [Abstract][Full Text] [Related]
15. A PCR-Based Approach for Driver Mutation Analysis of EGFR, KRAS, and BRAF Genes in Lung Cancer Tissue Sections.
de Oliveira Cavagna R; Leal LF; de Paula FE; Bernardinelli GN; Reis RM
Methods Mol Biol; 2021; 2279():109-126. PubMed ID: 33683689
[TBL] [Abstract][Full Text] [Related]
16. EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma.
Chalela R; González-García JG; Khilzi K; Curull V; Sánchez-Font A; Longarón R; Rodrigo-Calvo MT; Martín-Ontiyuelo C; Gea J; Bellosillo B
Pathol Oncol Res; 2021; 27():598292. PubMed ID: 34257550
[TBL] [Abstract][Full Text] [Related]
17. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
[TBL] [Abstract][Full Text] [Related]
18. Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma.
DeMaio A; Clarke JM; Dash R; Sebastian S; Wahidi MM; Shofer SL; Cheng GZ; Li X; Wang X; Mahmood K
J Bronchology Interv Pulmonol; 2019 Apr; 26(2):96-101. PubMed ID: 30048416
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
